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Abstract
Objective: Increased knowledge of breast cancer risk factors enables a shift from
one‐size‐fits‐all breast cancer screening to a risk‐based approach, tailoring screening
policy to a woman's individual risk. New opportunities for prevention will arise.
However, before this novel screening and prevention program is introduced, its
acceptability from a woman's perspective needs to be explored.
Methods: Women eligible for breast cancer screening in the Netherlands, United
Kingdom, and Sweden were invited to take part in focus groups. A total of 143
women participated. Data were transcribed verbatim and analyzed using thematic
analysis.
Results: Analysis identified five themes across the three countries. The first theme
“impact of knowledge” describes women's concern of not being able to unlearn their
risk, perceiving it as either a motivator for change or a burden which may lead to
stigma. The second theme “belief in science” explains women's need to trust the
science behind the risk assessment and subsequent care pathways. Theme three
“emotional impact” explores, eg, women's perceived anxiety and (false) reassurance,
which may result from knowing their risk. Theme four “decision making” highlights
cultural differences in shared versus individual decision making. Theme five “attitude
to medication” explores the controversial topic of offering preventative medication
for breast cancer risk reduction.
Conclusions: Acceptability of risk‐based screening and prevention is mixed.
Women's perceptions are informed by a lack of knowledge, cultural norms, and com-
mon emotional concerns, which highlights the importance of tailored educational
materials and risk counselling to aid either shared or individual informed decision
making.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2019 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.
Received: 3 December 2018 Revised: 27 February 2019 Accepted: 1 March 2019
DOI: 10.1002/pon.5051
1056 Psycho‐Oncology. 2019;28:1056–1062.wileyonlinelibrary.com/journal/pon
KEYWORDS
acceptability, attitudes, breast cancer, oncology, prevention, risk prediction, risk stratification,
screening
1 | BACKGROUND
Population‐based breast cancer screening programs, adhering to a
one‐size‐fits‐all approach based on age, have successfully led to early
detection and subsequent breast cancer mortality reduction.1,2
However, screening may become more effective if tailored to
women's differing levels of breast cancer risk, potentially optimizing
the benefit‐harm ratio of screening.3 Breast cancer risk prediction
models are becoming more accurate by adding, eg, breast density
and polygenic risk score to classic risk factors.4 Risk prediction also
offers new opportunities for breast cancer prevention, targeting
women who would benefit most from reducing their risk through life-
style changes or risk‐reducing medication. Successful implementation
of risk‐based screening and prevention relies on women's participa-
tion. However, eligible women's perceptions of adopting this novel
program have never been explored.
A risk‐based screening and prevention program is inherently more
complex than current age‐based screening programs. Women need to
reflect on participation at different stages (Figure 1). Although
Figure 1 is an illustration which does not necessarily follow current
pathways of care, it shows that women need to decide whether they
(a) want to know their risk, (b) are willing to change their screening
strategy based on risk, and (c) are prepared to participate in preventa-
tive practices. Women's interest in knowing their breast cancer risk is
high.5 However, knowledge of their risk did not lead to any consistent
changes in screening or preventative behaviours.6 Additionally,
although women generally appear in favor of increased screening for
high‐risk women, lowering screening intensity for low‐risk women is
more contested.7,8 Women are concerned about the accuracy of breast
cancer risk estimates with some believing that risk‐based screening is
mainly motivated by a desire to save money.8 Their perceptions of
prevention also seem mixed.7 However, risk‐reducing medication has
mostly been discussed with high‐risk womenwho tend to bemonitored
outside of national screening programs, which potentially limits the
generalizability of these results to the screening population.
Risk‐based screening may bring about considerable benefits to
healthcare policy by directing screening and preventative resources to
women who are most in need.9 However, there is a lack of
knowledge on the acceptability of an integrated risk‐based breast
cancer screening and prevention program from the perspective of
FIGURE 1 Illustration of a risk‐based breast cancer screening and prevention program. *Current screening guidelines: Netherlands (NL): women
aged 50 to 75 years old, screening interval 2 years; Sweden (SE): women aged 40 to 75 years old, screening interval 1.5 to 2 years; United
Kingdom (UK): women aged 50 to 70 years old, screening interval 3 years
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European women who would be eligible to participate, ie, women at
population‐level risk who meet current age criteria for screening.
Therefore, this study aims to evaluate the adoption of risk‐based breast
cancer screening and prevention by exploring perceptions of women
who participated in the well‐established national screening programs
of the Netherlands (NL), the United Kingdom (UK), and Sweden (SE).
Screening eligibility in these countries is solely based on age, without
access to additional risk information or screening modalities. Therefore,
risk‐based screening would be a considerable departure from current
age‐based screening practices in these three countries.
2 | METHODS
2.1 | Design
Focus groups (FGs) following a semistructured interview guide were
performed to explore women's perceptions of adopting risk‐based
breast cancer screening and prevention in NL, UK, and SE. Ethics
approval was acquired from the regional ethics committee CMO
Arnhem‐Nijmegen (2015‐1773) in NL, London Central NHS Research
Ethics Committee (16/LO/0925) in UK, and the Regional Ethical
Review Board at the Karolinska Institutet Stockholm (2017/375‐31/
2) in SE. Written (NL and UK) or verbal (SE) informed consent was
obtained from all participants prior to the start of the FGs. The partic-
ipant selection process and procedure are described in Data S1.
2.2 | Data analysis
Data were thematically analyzed per country, independently by pairs
of two researchers (L.R. and D.vd.W., L.R. and M.B., and Y.W. and
A.J.) using an inductive approach.10 Six stages were adhered to during
analysis, ie, familiarization with the data, coding, developing themes,
reviewing themes, defining and naming themes, and final analysis.10
Consensus was reached through discussion when discrepancies arose.
Descriptive analyses were performed with IBM SPSS version 22
(Armonk, NY: IBM Corp).
3 | RESULTS
3.1 | Participants
From the 1650 women invited to take part, 143 women participated
across the three countries (8.7%). Participant characteristics are
outlined in Data S2. Nine FGs were conducted in NL (54 participants),
five in SE (38 participants), and six in UK (51 participants). Group sizes
ranged from 5 to 10 participants. Swedish participants were consider-
ably older than Dutch and British participants: median ages 67.0, 57.5,
and 56.0, respectively. British women had fewer years of education
(median: 15.0) than Dutch (17.0) and Swedish women (21.0). More
British women had a first‐degree family history of breast cancer
(47.1%), than Dutch (16.7%) and Swedish women (21.1%). British
women showed a marked discrepancy between their perceived breast
cancer risk and their actual risk as relayed by the PROCAS study team.
Most British participants had a high risk of developing breast cancer
(70.6%); however, only 23.5% of participants perceived their risk as
high. No participants had a below average breast cancer risk.
3.2 | Thematic analysis
Dutch and Swedish women were generally positive about receiving
breast cancer risk feedback. None of the British women expressed
regret about finding out their risk. Women in all three countries
emphasized, however, that participation should be optional, offering
screening according to current country guidelines to women who do
not want to adopt this approach. Figure 2 displays the themes
representing perceptions of the adoption of risk‐based screening and
prevention of Dutch, Swedish, and British women. Data S3 provides
a breakdown of the themes per country with relevant quotes. In
general, there was extensive overlap in perceptions of women across
the three countries. Therefore, we were able to identify five superor-
dinate themes: (1) impact of knowledge, (2) belief in science, (3)
emotional impact, (4) decision making, and (5) attitude to medication.
Although the overarching themes showed similarities, subthemes
sometimes differed per country. Both will be discussed below using
FG data extracts.
3.2.1 | Theme 1. Impact of knowledge (NL, SE,
and UK)
The superordinate theme “impact of knowledge” deals with women's
perception that once they know their breast cancer risk, they feel
the need to act upon that information. A moderate‐high risk result in
particular elicited either a beneficial response, ie, the subthemes per-
ceived control, proactive attitude, motivation, and empowerment, or
was perceived as a burden, ie, avoidance, guilt, and fatalistic view. As
a Swedish participant put it, “A high risk result almost feels like it's
close to a diagnosis.” British participants, who had chosen to have
their breast cancer risk relayed, generally perceived knowledge of risk
as an opportunity: “Perhaps being more aware, and doing something
proactively about your high risk, makes you feel more in control, and
so you're less stressed.” Although women in all three countries
generally welcomed preventative options to manage their risk, they
also mentioned the potential for stigma and guilt, eg, “It puts a lot of
responsibility for health on women and not everyone is equally
capable of maintaining a healthy lifestyle; financially or intellectually.
It can't become a woman's own fault if she develops breast cancer”
(Dutch participant).
3.2.2 | Theme 2. Belief in science (NL, SE, and UK)
The superordinate theme “belief in science” illustrates women's con-
cerns regarding the scientific basis of the risk prediction model and
the effectiveness of risk‐reducing medication and lifestyle changes.
Dutch women were particularly concerned about extending the
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screening interval for women at below average risk, wondering
whether it is financially motivated rather than evidence‐based.
Swedish women displayed a greater trust in the scientific evidence
behind any new screening policy, eg, “Yes, personalised screening
intervals are acceptable provided you know how they are developed
and what the criteria are: why some women are asked to go for a
screening more often than others.” Dutch women also described the
role of perceived breast cancer risk in the acceptability of a personal-
ized screening plan. They believe that if their relayed risk does not cor-
respond to their perceived risk, they will be less likely to accept the
accompanying screening and prevention advice. Both British and
Dutch women were skeptical about the scientific link between life-
style changes and breast cancer risk. The acceptability of risk‐reducing
medication depended on the magnitude of the effect, with women
balancing the potential for adverse effects and risk reduction. More-
over, women would like to monitor the effect of preventative mea-
sures to determine potential reclassification of risk: “So, I think, if
you can really see, find out that you have made a difference through
prevention, then you could potentially screen less frequently. Particu-
larly if you have changed your risk” (Swedish participant).
3.2.3 | Theme 3. Emotional impact (NL and UK)
The superordinate theme “emotional impact” describes how women
think risk‐based screening and prevention will affect their psychologi-
cal wellbeing, with the subthemes: awareness, anxiety, (false) reassur-
ance, and impact on quality of life. These themes were more prevalent
in Dutch and British women's perceptions, whereas Swedish women
phrased their perceptions in more rational terms, with fewer refer-
ences to emotional states, eg, “But, if they determine you have a
higher risk of developing breast cancer, surely, that doesn't mean
you'll definitely get it. Because there are other contributing factors
too.” The main difference between British and Dutch women's
perceptions concerned the level of reassurance. The majority of Dutch
women did not perceive the hypothetical message of below average‐
average risk to be particularly reassuring: “It remains a risk and it is
never no risk; even if you tell me I have a 95% chance of not develop-
ing breast cancer, I might still be in the 5%; it doesn't provide real
reassurance.” However, British women who actually received their
risk, indicated that receiving a letter stating that you have an average
risk of developing breast cancer was very reassuring, filing the letter
and forgetting all about it. Dutch women worried that they would
become preoccupied: “I don't want to know my risk, because it will
make me worry about every little ache or change in my breast.” Some
British women at high risk described needing professional help: “It has
massive impact, because I'm still undecided with the treatments I've
been offered, what to do. So I'm seeing a clinical psychologist.”
Women from both counties worried about the impact that risk‐
reducing medication would have on their current quality of life due
to potential adverse effects.
3.2.4 | Theme 4. Decision making (SE and UK)
“Decision making” is a superordinate theme that received specific
attention during the British and Swedish FGs. Swedish women empha-
sized individual decision making, considering the process a personal
responsibility, balancing anecdotal knowledge of breast cancer and
preventative options, and the impact that the risk assessment and sub-
sequent recommendations may have on the quality of life of others
and yourself: “I don't think I'd consult anyone about the actual deci-
sion, because the decision is for me to make. It's my responsibility.”
British women on the other hand emphasized a shared decision
making process with family, friends, and professionals, taking into
account responsibility to oneself and family, and potential life events
that could influence decision making, eg, divorce and illness. Profes-
sional endorsement appeared particularly elementary in the adoption
of risk‐reducing medication, with British women who were at first
adverse to the idea of medication changing their mind due to profes-
sional advice: “Well, for me it was a no‐brainer because, I mean, I don't
like the idea of taking tablets constantly, I just don't like it. But the
doctor said it was a no‐brainer for me personally, you know, because
of the advantages.” British women were also influenced more by
media coverage about breast cancer, speaking of the perceived
ubiquitous nature of the disease: “Not through being told, but I think
because it's constantly in the media, breast cancer, I don't think even
if you're average you feel safe.”
FIGURE 2 Overview of the themes associated with Dutch, English, and Swedish women's perceptions of risk‐based breast cancer screening and
primary prevention. *Agreement in themes is displayed in bold. Figure adapted from Fritzell et al 201711
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3.2.5 | Theme 5. Attitude to medicine (NL and UK)
The superordinate theme “attitude to medicine” reflects the apparent
controversial nature of risk‐reducing medication for breast cancer,
which was mostly addressed by British and Dutch women. Swedish
women tended to have a more pragmatic approach to medication,
stating that they preferred lifestyle changes but that they would be
willing to try medication to determine the level of adverse effects.
Most Dutch women, however, expressed an aversion to medication,
perceiving it to be a radical and unnecessary daily hassle when dealing
with a risk instead of a diagnosis. Anecdotal knowledge of particularly
tamoxifen as a breast cancer drug induced worry and anxiety. Some
Dutch women argued that preventative medication is normalized,
referring to, eg, cardiovascular medication, reasoning that medication
is a convenient and easy solution to lower your risk. A considerable
number of British women who participated in the FGs had been
advised to take risk‐reducing medication. Although the British
women's attitudes to medicine were very similar to Dutch women's,
they generally opted to take it, with one participant stating: “Most of
us think it's worth the risk.”
4 | DISCUSSION
The present study provides an overview of British, Dutch, and
Swedish women's perceptions of adopting risk‐based breast cancer
screening and prevention. To our knowledge, this is the first study of
its kind that has been performed in a population‐based European
screening setting. It showed that, overall, women appear in favor of
finding out their breast cancer risk, although the acceptability of sub-
sequent screening and preventative strategies is mixed. Importantly,
women emphasize that strategies should be evidence‐based and par-
ticipation voluntary. There is considerable overlap in the perceptions
of women across the three countries. This suggests that the variation
in hypothetical (NL and SE) versus “actual” (UK) risk scenarios did not
hinder women's ability to participate in the discussion. However,
Swedish women experienced more difficulty than Dutch women
relating to both the concepts of risk and hypothetical risk scenarios,
requiring more clarification and encouragement to start a discussion.
The superordinate themes associated with women's perceptions of
risk‐based screening and prevention across the three countries are
rooted in behavioral theory. Women's perceptions seem to be best
reflected by the “health belief model” and “self‐determination
theory”.12,13 These two theoretical frameworks assume a cost‐benefit
analysis of particular health behaviors, whereby a person takes into
account perceived severity and susceptibility to disease, psychological
factors, social context, autonomy, and personal competence. The
relevance of these two frameworks to the adoption of this novel
screening and prevention paradigm by women has previously been
demonstrated.7 However, the way in which the underlying constructs
of the theoretical frameworks are represented in women's perceptions
sometimes differs across the three countries, potentially pointing to
culture‐specific attitudes or customs.
Cross‐cultural concordance was seen in the themes “impact of
knowledge” and “belief in science”. Women from all three countries
deliberated that breast cancer risk information may not be without
consequence, enticing activity, or potential emotional turbulence.
The importance of perceived competence in health behavior decision
making is highlighted. Dutch and Swedish women reported a great
need to understand the scientific basis of the risk prediction model
and subsequent screening and prevention recommendations. They
appear to perceive a greater sense of control when more knowledge-
able. However, research shows that risk information is difficult to
understand.14 A comprehensive information leaflet, which meets all
of women's perceived information needs, may therefore hinder
informed decision making. This is in accordance with the attitude of
British women in this study who only received a basic level of informa-
tion at every stage of the program but did not report a perceived lack
of information or knowledge. The theme “belief in science” also
highlighted some women's skepticism about the accuracy of risk esti-
mates and the rationale behind risk‐based screening, suspecting a
financial motive. These concerns were previously mentioned by US
women who professed a reluctance to change current screening
habits, fearing missed breast cancers with a changed screening
interval.8
The emotional impact of risk assessment was hypothesized by
Dutch women and reported by British women about a year after
receiving risk feedback. Some British women who were classified as
moderate‐high risk reported a decrease in psychological well‐being
with some women seeking professional help. These findings are
tentatively confirmed by a survey study among PROCAS participants
who received breast cancer risk feedback and PROCAS participants
who were awaiting their risk feedback.6 Women who had received
their risk feedback reported lower levels of anxiety but higher levels
of cancer worry than women awaiting their risk feedback. Additionally,
women with a moderate‐high risk of developing breast cancer
reported higher anxiety than women with a below average risk. How-
ever, overall anxiety levels were still relatively low. This is in line with
previous research showing no significant long‐term impact of genetic
risk estimation on psychological outcomes.15
A pronounced difference between Swedish and British women's
perceptions was visible in the decision making process precipitating
participation. Swedish participants favored a more autonomous pro-
cess than British participants, who emphasized a shared approach.
Previous studies have found that medical decision making is affected
by gender, age, and education, with younger, highly qualified women
being most likely to desire higher levels of autonomy.16 This partially
corresponds with our findings since Swedish women were, on aver-
age, more educated than British women. However, Swedish women
were also considerably older on average than British women, contra-
dicting previous findings. Moreover, a qualitative study of Swedish
people's values regarding participation in colorectal cancer screening
showed a similar need for autonomy, pointing to a potential societal
attitude.11
The superordinate theme “attitude to medicine” shows a general
reluctance of women to try risk‐reducing medication. Particularly
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noteworthy is the reliance of British women on professional endorse-
ment in the decision making process. Although our British participants
were generally not in favor of medication, professional endorsement
changed their views almost unanimously. This is in concordance with
previous research suggesting that people look to physicians for
decisions on medication use, because of their perceived superior
knowledge.16 It is unclear whether the unfavorable opinion of Dutch
and Swedish women regarding risk‐reducing medication is related to
the hypothetical nature of the risk scenarios. However, Dutch women
are known for their reluctance to take medication,17 which is sup-
ported by the relatively low number of women reporting
current/past HRT use in this study. Breast cancer risk reduction
through medication is notoriously difficult to achieve, with few
women showing willingness to commit to a 5‐year preventative treat-
ment regimen.18,19 The use of tamoxifen as a preventative drug elicits
a strong response from women because of the association with breast
cancer treatment.20 Additionally, the perceived adverse effects
often deter women,19,20 which was confirmed in the present study.
Currently, studies are being undertaken, eg, KARMA Intervention
Study (KARISMA) in SE (https://karmastudy.org/ongoing‐research/),
to determine the lowest effective dose of tamoxifen to potentially
increase its applicability as a preventative drug.
5 | CONCLUSIONS
5.1 | Study limitations
The present study is the first exploration of European women's per-
ceptions of adopting an integrated risk‐based breast cancer screening
and prevention program. The large number of women from three
European countries allowed for an extensive cross‐cultural exploration
of the acceptability of this new paradigm from the perspective of
potential future participants. However, we have to be careful in our
interpretation of the results and culture‐specific variations cannot be
assumed. Selection bias is likely to have affected group composition
in all three countries. In general, FG participants were relatively highly
educated women who had previously participated in breast cancer
screening and scientific research. They were more likely to have had
favorable perceptions of screening, potentially limiting the generaliz-
ability of our findings to women who do not currently participate in
screening. Moreover, an unequal number of British women were
invited per risk category, which led to an overrepresentation of high‐
risk women. Below average risk women were not at all represented,
although some women reported a low perceived breast cancer risk.
Moreover, perceptions of Dutch and Swedish women could have been
affected by the hypothetical nature of the risk scenarios with inher-
ently lower stakes. Additionally, FGs were moderated by different
researchers due to a language barrier. Although we relied on a
semistructured interview guide to standardize discussion, variation is
plausible. Future research is required to confirm the identified percep-
tions in a larger group of women. We are therefore currently
performing a survey study aiming for equal representation of women
with below average, average, and above average breast cancer risk
who are eligible for screening.
5.2 | Clinical implications
Acceptability of risk‐based screening and prevention is mixed. More
intensive screening for women with above average breast cancer risk
was generally welcomed. However, screening pathways for the other
risk categories and general prevention strategies were met with some
skepticism. This has implications for clinical practice that need to be
addressed by stakeholders and policy makers before implementation.
Women's perceptions seem to be informed by a lack of knowledge,
cultural norms, and common emotional concerns, which highlights
the importance of tailored educational materials and risk counselling
to aid either shared or individual informed decision making.
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